12 Best Small-Cap Healthcare Stocks To Buy Now

Published on December 12, 2022 at 3:44 pm by Hamna Asim in Hedge Funds, News

In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now.

Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. As per PwC, growing transaction volumes and market players focusing on value-based care, paired with high levels of cash stockpiles and private equity “dry powder”, are resulting in ongoing expansion for deal volumes in 2023. Nick Donkar, PwC’s U.S. health services deals leader, expects a resilient outlook for health services M&A activity in 2023 with companies majorly exploring M&A, divestitures, and similar transactions. Donkar stated in an interview on December 8:

“The deal market in 2022 was fairly robust coming off an unprecedented banner year, which was 2021. Obviously, 2021 was the highest deal volume we’ve experienced from a health services perspective. We’re happy to see the health of the overall market, no pun intended, with respect to the level of volume and activity that has been exhibited thus far in 2022.”

Nick Donkar categorized the healthcare space as almost “recession-proof“, noting that innovation, technological advancements, and high investment continues to improve patient care. Investors usually gravitate towards healthcare stocks like AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT). However, we discuss some of the top small-cap healthcare stocks in this article.

Our Methodology

We selected the following healthcare stocks based on positive analyst coverage, strong business fundamentals, and market visibility. These firms have a market cap of between $300 million to $2 billion as of December 12. We have assessed the hedge fund sentiment from Insider Monkey’s database of 920 elite hedge funds tracked as of the end of the third quarter of 2022.

Photo by National Cancer Institute on Unsplash

Best Small-Cap Healthcare Stocks to Buy Now

12. Addus HomeCare Corporation (NASDAQ:ADUS)

Number of Hedge Fund Holders: 10

Market Capitalization as of December 12: $1.662 Billion

Addus HomeCare Corporation (NASDAQ:ADUS) is a Texas-based company that provides personal care services to the elderly, chronically ill, disabled persons, and individuals at risk of hospitalization in the United States. It operates through three segments – Personal Care, Hospice, and Home Health. It is one of the best healthcare stocks to consider.

RBC Capital analyst Frank Morgan on November 2 raised the price target on Addus HomeCare Corporation (NASDAQ:ADUS) to $121 from $110 and maintained an Outperform rating on the shares. The company’s Q3 results were “solid” as organic Personal Care segment volume growth of 7% outperformed management’s expectations, the analyst told investors in a research note. He added that he is also encouraged by signs of a feasible hospice backdrop in October, as well as Addus HomeCare Corporation (NASDAQ:ADUS)’s improved hiring.

According to Insider Monkey’s data, 10 hedge funds were bullish on Addus HomeCare Corporation (NASDAQ:ADUS) at the end of September 2022, compared to 13 funds in the prior quarter. The collective stakes held by elite funds in Q3 2022 increased to $45 million from $44 million in Q2 2022. Brian Ashford-Russell and Tim Woolley’s Polar Capital held the largest position in the company, comprising 346,297 shares worth $33 million.

Like AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT), Addus HomeCare Corporation (NASDAQ:ADUS) is one of the best healthcare stocks to invest in.

11. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Number of Hedge Fund Holders: 11

Market Capitalization as of December 12: $1.914 Billion

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a California-based surgical robotics company that manufactures transformative solutions in urology. It develops and sells AquaBeam Robotic System, an image-guided, surgical robotic system for minimally-invasive urologic surgery focused on treating benign prostatic hyperplasia. On November 3, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) posted a Q3 revenue of $20.35 million, up 134.7% year-over-year, beating Wall Street estimates by $3.12 million. The company increased fiscal year 2022 total revenue guidance to approximately $72.5 million, representing growth of 110% compared to 2021, versus a consensus of $67.51 million.

On November 14, Truist analyst Richard Newitter raised the price target on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) to $58 from $56 and maintained a Buy rating on the shares. The analyst’s meeting with PROCEPT BioRobotics Corporation (NASDAQ:PRCT) management offered positive takeaways as the company believes it has a good handle on the two main issues that led to the FY22 guide down. The company’s CEO also indicated a high level of confidence that the impact from these issues is temporary and should be largely resolved by early 2023 or sooner, the analyst told investors in a research note.

According to Insider Monkey’s Q3 data, 11 hedge funds were bullish on PROCEPT BioRobotics Corporation (NASDAQ:PRCT), compared to 12 funds in the preceding quarter. Richard Driehaus’ Driehaus Capital is the leading position holder in the company, with 870,874 shares worth $36 million.

10. Krystal Biotech, Inc. (NASDAQ:KRYS)

Number of Hedge Fund Holders: 15

Market Capitalization as of December 12: $1.829 Billion

Krystal Biotech, Inc. (NASDAQ:KRYS) is a Pennsylvania-based clinical stage biotechnology company that specializes in redosable gene therapy to treat serious rare diseases in the United States. It is one of the best healthcare stocks to consider. On November 17, Krystal Biotech, Inc. (NASDAQ:KRYS)’s Jeune Aesthetics subsidiary announced that phase 1 data from an extension cohort indicated that KB301, a gene-based treatment developed to address the underlying biology of aging skin to treat wrinkles and fine lines, indicated durability over nine months. Jeune now plans to start a phase 2 study of KB301 in H1 2023.

On November 7, Chardan analyst Geulah Livshits raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $133 from $130 and kept a Buy rating on the shares. Following Q3 results, the analyst noted that Krystal Biotech, Inc. (NASDAQ:KRYS) now expects to continue patient dosing with topical KB105 in the next cohort of the Phase II in TMG1-mediated ARCI in early 2023.

According to Insider Monkey’s third quarter database, Krystal Biotech, Inc. (NASDAQ:KRYS) was part of 15 hedge fund portfolios, compared to 12 in the prior quarter. The combined stakes held by elite funds in Q3 2022 increased to $389 million from $386.4 million in Q2 2022. Jeremy Green’s Redmile Group is the biggest stakeholder of the company, with approximately 2 million shares worth $132.4 million.

9. Nuvalent, Inc. (NASDAQ:NUVL)

Number of Hedge Fund Holders: 15

Market Capitalization as of December 12: $1.75 Billion

Nuvalent, Inc. (NASDAQ:NUVL) was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. It is a clinical stage biopharmaceutical company that develops therapies for patients with cancer. On October 28, Nuvalent, Inc. (NASDAQ:NUVL) reported initial data from the phase 1 part of a phase 1/2 trial of NVL-520 to treat patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors. The trial had a favorable safety profile and provided positive results. Nuvalent, Inc. (NASDAQ:NUVL) stock climbed 72% upon reporting the data. It is one of the best healthcare stocks to monitor.

On October 28, BMO Capital analyst Etzer Darout raised the price target on Nuvalent, Inc. (NASDAQ:NUVL) to $50 from $28 and kept an Outperform rating on the shares. The analyst cited the company’s initial dose escalation data for NVL-520, which he thinks serves as a clear indicator of its value proposition. Through the data cutoff, there were no treatment-related critical adverse events, the analyst told investors in a research note.

Among the hedge funds tracked by Insider Monkey, Nuvalent, Inc. (NASDAQ:NUVL) was part of 15 public stock portfolios at the end of September 2022, compared to 12 in the earlier quarter. James E. Flynn’s Deerfield Management is the largest stakeholder of the company, with 19.3 million shares worth $376 million.

8. Xencor, Inc. (NASDAQ:XNCR)

Number of Hedge Fund Holders: 16

Market Capitalization as of December 12: $1.755 Billion

Xencor, Inc. (NASDAQ:XNCR) is a California-based clinical stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. In Q3 2022, Xencor, Inc. (NASDAQ:XNCR) reported a revenue of $27.3 million, up 38.7% year-over-year, outperforming estimates by $6.25 million. The company expects to conclude 2022 with about $575 million to $600 million in cash, cash equivalents, receivables, and marketable debt securities. It is one of the best small-cap healthcare stocks to invest in.

On December 6, Cowen analyst Boris Peaker initiated coverage of Xencor, Inc. (NASDAQ:XNCR) with an Outperform rating without a price target. He forecasts Xencor, Inc. (NASDAQ:XNCR)’s partnered programs to generate revenue of up to $3 billion over the next decade from milestone and royalty payments, said the analyst, who also expects the company’s completely owned programs to “create further value as they advance.”

According to Insider Monkey’s Q3 data, 16 hedge funds were bullish on Xencor, Inc. (NASDAQ:XNCR), compared to 14 in the prior quarter. Oleg Nodelman’s EcoR1 Capital is the biggest stakeholder of the company, with 5.2 million shares worth $137.2 million.

7. Immunovant, Inc. (NASDAQ:IMVT)

Number of Hedge Fund Holders: 17

Market Capitalization as of December 12: $1.871 Billion

Immunovant, Inc. (NASDAQ:IMVT) is a New York-based clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of autoimmune diseases. On November 7, H.C. Wainwright analyst Douglas Tsao raised the price target on Immunovant, Inc. (NASDAQ:IMVT) to $17 from $16 and kept a Buy rating on the shares. The company had a “fairly uneventful earnings release after a period of significant activity,” the analyst told investors in a research note.

According to Insider Monkey’s data, Immunovant, Inc. (NASDAQ:IMVT) was part of 17 hedge fund portfolios at the end of the third quarter of 2022, with collective stakes worth $97 million, compared to 11 in the prior quarter worth $48.8 million. David Kroin’s Deep Track Capital is the leading position holder in the company, with 9.86 million shares worth $55 million.

6. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Number of Hedge Fund Holders: 18

Market Capitalization as of December 12: $1.705 Billion

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological diseases in the United States. On November 9, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported a Q3 non-GAAP EPS of $0.26 and a revenue of $57.24 million, outperforming Wall Street estimates by $0.07 and $3.55 million, respectively. Revenue for the period climbed 59.2% on a year-over-year basis. The company also raised its full-year 2022 forecast for total revenues to be in the range of between $205 million and $210 million, representing a 46% to 49% increase compared to 2021, versus a consensus of $205.03 million.

On November 10, Piper Sandler analyst Joseph Catanzaro raised the price target on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to $18 from $16 and maintained an Overweight rating on the shares. The company reported Q3 Firdapse revenues of $57.2 million, which were well above consensus, and raised Firdapse revenue to $205 million-$210 million, the analyst told investors. Firdapse continues to grow, supported by a low discontinuation rate and organic growth, including higher enrollment of tumor-LEMS patients, the analyst added.

According to Insider Monkey’s Q3 data, 18 hedge funds were bullish on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), compared to 16 in the prior quarter. Jim Simons’ Renaissance Technologies is a prominent stakeholder of the company, with 2.2 million shares worth $28.5 million.

In addition to AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT), Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the top stocks to consider for exposure to the healthcare sector.

Click to continue reading and see 5 Best Small-Cap Healthcare Stocks To Buy Now.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up